Abstract
In the past few years, adalimumab has become an important drug for dematologists, used in severe cases of chronic psoriasis and hidradenitis suppurativa. Its effectiveness and safety have been proven in clinical trials and it can be axpected that the indications of adalimumab treatment will widen in the future, including other severe dermatoses.